Stock AQST AQUESTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
3.11 USD -5.18% Intraday chart for Aquestive Therapeutics, Inc. +0.65% +53.96%
May. 10 Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target MT
May. 08 Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
GL
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
AQ
Aquestive Therapeutics: Q1 Earnings Snapshot
AQ
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
GL
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
GL
Aquestive Therapeutics to Present Crossover Study Data for Libervant Buccal Film at 76th Annual Meeting of the American Academy of Neurology
AQ
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
GL
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
GL
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
AQ
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
GL
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
GL
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
GL
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
GL
Aquestive Therapeutics: Q4 Earnings Snapshot
AQ
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GL
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
GL
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
GL
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
GL
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm Sublingual Film
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AQST Stock
  4. News Aquestive Therapeutics, Inc.
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW